Napo Pharmaceuticals, Inc.  

San Francisco,  CA 
United States
  • Booth: 2006

Welcome! Napo Pharmaceuticals hopes you enjoy DDW 2017!

Napo Pharmaceuticals, Inc. develops novel pharmaceuticals for the global marketplace. Mytesi™ (crofelemer) is the first product developed by Napo. Mytesi is FDA-approved and available in the US. 
Napo sources the raw material for Mytesi from a tree (Croton lechleri) in the Amazon rainforest. The raw material is the purified to crofelemer, the active ingredient in Mytesi. Napo has established a sustainable harvesting program for crofelemer that plants two new trees for each one harvested.
Learn more about Mytesi at 
Please visit Napo at Booth #2006

Brands: Mytesi™ (crofelemer)


  • Mytesi (crofelemer)
    Mytesi (crofelemer) is FDA-approved in the US and available now. Mytesi is the only......

  • In adult HIV patients on ART who have noninfectious diarrhea

    Mytesi (crofelemer) is the only antidiarrheal studied in and FDA-approved for relief of diarrhea in adults living with HIV/AIDS. 

    • Mytesi treats diarrhea differently by normalizing the flow of water in the GI tract
    • Mytesi is not an opioid and does not affect GI motility

    Mytesi has been proven to have: 

    • Minimal absorption, with plasma concentrations below the level of detection
    • No clinically relevant drug-drug interactions
    • No effect on viral load or CD4 counts
    • Adverse events comparable to those with placebo

    Important Safety Information about Mytesi 

    Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Please see Full Prescribing Information at

    NP 399-7

 Additional Info

DDW Tracks
Microbiome in Gastrointestinal and Liver Diseases, Inflammatory Bowel Diseases, Liver Diseases and Transplantation, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Functional GI and Motility Disorders, Pancreatic Diseases, Biliary Tract Diseases
Does your company only service US attendees?
Is your company a new exhibiting company?

For Marketing Opportunities offered by our partner TriStar, click here